To Top

Search By Topic

Cell and Gene Therapy

72 Articles available
Genetics

New Genetic Understanding Could Lead to Brain Cancer Treatments

PAO-M09-18-NI-017
Drug Development

Sanofi-Aventis Collaborates with Dyadic International on Cl Gene Expression

PAO-M09-18-NI-007
CRISPR

CRISPR is Helping Dogs with Muscular Dystrophy and Young Boys Could be Next

PAO-M08-18-NI-030
Regenerative Medicine Therapies

Affordable Regenerative Stem Cell Therapy is Now Offered Through Zen Care Physical Medicine in Irvine at an Extraordinary Value

PR-M08-18-NI-094
Cell and Gene Therapy

MedImmune and 4D Molecular Therapeutics Collaborate to Design, Develop and Commercialize AAV Gene Therapy for Chronic Lung Disease

PR-M07-18-NI-038
Investment

Evonetix Awarded Innovate UK Funding for £1.3 Million Gene Synthesis Project

PR-M07-18-NI-023
Genome

Precision BioSciences Raises $110M to Advance ARCUS Genome Editing Programs

PR-M06-18-NI-093
Genome

Johnson & Johnson Innovation Opens JLABS @ NYC in Collaboration with New York State and the New York Genome Center

PR-M06-18-NI-075
Cell and Gene Therapy

Will Rapid Genome Sequencing Become A Standard Practice for Acutely Ill Infants?

PAO-M06-18-NI-012
Cell and Gene Therapy

BridgeBio Pharma Launches CoA Therapeutics to Target Coenzyme-A for Rare Genetic Disorders

PR-M06-18-NI-052
Cell and Gene Therapy

StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform

PR-M06-18-NI-054
Drug Discovery

Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts

PR-M06-18-NI-044
Cell and Gene Therapy

Global Gene Therapy Market Opportunity Analysis and Industry Forecast, 2023

PR-M06-18-NI-043
Viral Vector

Flexible, Mobile, Modular: High-Containment Viral Vector Center of Excellence

PAP-Q2-18-CL-005
Cell and Gene Therapy

Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing

PAP-Q2-18-CL-011
Cell and Gene Therapy

Editas Founders Start New Gene Editing Company

PAO-M05-18-NI-011
FDA Guidance

FDA finalizes guidances to accelerate the development of reliable, beneficial next generation sequencing-based tests

PR-M04-18-NI-54
Drug Discovery

"Transcriptional wiring" of cancer genes can be resolved using Lexogen's SLAMseq and QuantSeq technologies to facilitate drug discovery

PR-M04-18-NI-38
Cell and Gene Therapy

New Stem Cell Therapy Approved in Europe

PR-M03-18-NI-102
Discovery

New ALS Gene Discovered: KIF5A

PR-M03-18-NI-091
Partnership

Nohla Therapeutics Selects Advanced Therapies Business Unit of WuXi AppTec to Manufacture Universal Donor Cell Therapies

PR-M03-18-NI-090
Capacity Expansion

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

PR-M03-18-NI-079
Cell and Gene Therapy

Oxford BioMedica is Making Big Moves

PAO-M03-18-NI-012
Viral Vector

Ensuring Confidence in Viral Vector Manufacturing

PAP-Q1-18-CL-012
Cell and Gene Therapy

MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

PR-M03-18-NI-022
Cell and Gene Therapy

Brammer Bio Supports Rare Disease Day 2018

PR-M03-18-NI-006
Oncology

Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer

PR-M02-18-NI-95
Market Expansion

Marken Accelerates Its Reach And Growth In Clinical Trial Logistics

PR-M02-18-NI-031
Financing

Engine Biosciences Raises $10 Million in Seed Financing to Accelerate Drug Discovery Using Genomics and Artificial Intelligence

PR-M02-18-NI-015
Cell and Gene Therapy

Cell Therapy Companies Can Now Have Improved Cell Thawing Capabilities

PAO-M01-18-NI-042
FDA Approval

U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer

PR-M01-18-NI-052
FDA

FDA Approves First Treatment for Breast Cancer with a Certain Inherited Genetic Mutation

PR-M01-18-NI-047
Announcement

Taxus Cardium Announces Name Change To Gene Biotherapeutics

PR-M01-18-NI-021
Biologics

New Class of Exosome Biologics Focuses on Stroke Treatment

PAO-M01-18-NI-011
CRISPR

Genetically Engineered Horses Could be a Reality

PAO-M01-18-NI-008
Drug Development

Array BioPharma Forms New Subsidiary Yarra Therapeutics

PAO-M01-18-NI-007
CAR T

Thermo Fisher Gets Key Customer for Its Cell Therapy Activation Reagents

PAO-M01-18-NI-006
Cell and Gene Therapy

FDA Approves Gene Therapy

PAO-M01-18-NI-005
Drug Delivery

Building DNA and RNA Origami for Drug Delivery

PAO-M01-18-NI-003
Acquisition

Gilead’s new Kite Subsidiary To Buy CAR-T Cell Therapy Company Cell Design Labs

PAO-M01-18-NI-001
DNA

New Method Could Provide Super Resolution for Biological Imaging

PAO-M12-17-NI-040
Drug Development

Memory T Cells Fit to be Cross Trained

PAO-M12-17-NI-027
CRISPR

Charles River Expands CRISPR Offerings with Second License

PAO-M12-17-NI-022
Cell and Gene Therapy

St. Jude Gene Therapy Improves Immunity In Babies With 'Bubble Boy' Disease

PR-M12-17-NI-008
Cell and Gene Therapy

Brammer Bio Completes Renovations at Manufacturing Site in Massachusetts

PAO-M12-17-NI-006
Regenerative Medicine

International Society for Cellular Therapy Supports New FDA Policy Framework for Regenerative Medicine

PAO-M12-17-NI-004
Strategic Partnership

New Collaboration Targets the Development of Oligonucleotides

PAO-M12-17-NI-002
Cell and Gene Therapy

Segregation in the Design of Gene Therapy Manufacturing Facilities

PAP-Q4-17-CL-002
Clinical Trials

Managing the Complexities of Outbound Clinical Drug Distribution

PAP-Q4-17-CL-001
Innovation

Developing Targeted Potassium Channel Openers for CNS-Related Therapeutics

PAP-Q4-17-CL-004
Acquistion

Kite Pharma Acquisition by Gilead Finalized

PAO-M10-17-NI-017
Cell and Gene Therapy

Gene Therapy Stabilizes Neurodegenerative Disease

PAO-M10-17-NI-013
FDA Approval

Novartis Receives First Ever FDA Approval For A CAR-T Cell Therapy, Kymriah(TM) (CTL019)

PR-M08-17-NI-010
Transient Transfection

Transient Transfection at a Large Scale for Flexibility in Clinical and Commercial Vector Manufacturing

PAP-Q3-17-CL-005
Cell and Gene Therapy

Shire Submits IND for Hemophilia A Gene Therapy

PAO-M07-17-NI-016
CDMO

Supporting the Tech Transfer Continuum for Cell & Gene Therapies

PAP-Q2-17-CL-003
CRISPR

MilliporeSigma Increases the Efficiency of Gene Editing

PAO-M05-17-NI-030
Continuous Manufacturing

Acoustics for Separation and Filtration of Applications

Stanley Kowalski III, Co-Founder, Chairman & CEO, FloDesign Sonics

PTV-M03-17-IN-008
Immuno-oncology Therapies

Combinational Immunotherapies: The Bright Future of Cancer Treatment

MCP-M04-17-NI-001
CDMO

Latest Developments in Cellular and Gene Therapies

MCP-M03-17-NI-001
Development

A New Type of Medicine: Biotherapeutics Usher in a New Era

Daniel Sikkema, VP Biologics Services, Frontage Labs

PTV-M11-16-AP-018
Biologics

Investing for Successful Advancement of Viral Vector Manufacturing

PAP-Q1-17-CL-007
Discovery

Move Toward Cell-Based Manufacturing Signals Opening in Vaccine Market

MCP-M02-17-NI-002
Biologics

Cell Line Development for Therapeutic Recombinant Proteins

MCP-M02-17-NI-001
API

A Look at Recent Pharma Industry Innovations

PAP-Q04-16-NO-001
CDMO

CDMOs Crucial for Bringing Promising Next-Generation Therapies to Market

PAP-Q03-16-CL-013
CDMO

Collaboration is the Name of the Game

PAP-Q03-16-IN-001
Biologics

Biosimilars: Are We on the Edge of a New Era of Biologics?

PAP-Q02-16-RT-002
CDMO

Achieving Large-Scale Cell and Gene Therapy Manufacturing

PAP-Q02-16-CL-010
Brammer Bio

Brammer Bio: Manufacturing Personalized

PAP-Q02-16-DL-001